{"id":"W2078057935","doi":"10.1007/s10637-011-9722-5","title":"A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"ca_institutions":"Juravinski Cancer Centre; London Health Sciences Centre; BC Cancer Agency","funders":"Bayer Canada","keywords":"Bicalutamide; Medicine; Sorafenib; Prostate cancer; Internal medicine; Oncology; Adverse effect; Clinical endpoint; Rash; Clinical trial; Cancer; Androgen receptor; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001242367,0.000134246,0.0002161422,0.0002438647,0.00004293686,0.000006944033,0.0000510691,0.00003757473,0.00004932162],"category_scores_gemma":[0.00001605562,0.00009309586,0.00001314753,0.0005474372,0.0001413633,0.0001765839,0.00001314818,0.0001396469,9.728882e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002245533,"about_ca_system_score_gemma":0.0007859248,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0028828,"about_ca_topic_score_gemma":0.001277994,"domain_scores_codex":[0.9986956,0.0000494052,0.0002927815,0.0002466382,0.0005403064,0.0001752834],"domain_scores_gemma":[0.9993703,0.00002235334,0.000133828,0.0001237279,0.0002329062,0.0001168558],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01619686,0.009656559,0.935629,0.00006228638,0.0001030024,0.0000318268,0.0326858,0.00004723925,0.001568783,0.0001907976,0.00006553331,0.003762305],"study_design_scores_gemma":[0.06624364,0.01281535,0.9122341,0.0003630192,0.00003458728,7.377312e-7,0.001039428,0.00009638777,0.006277745,0.0007607496,0.00001525761,0.0001189371],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970444,0.00003930346,0.000002632253,0.0008689182,0.0000132777,0.001809485,0.000019631,0.00001235669,0.0001900073],"genre_scores_gemma":[0.9987137,0.000009412815,0.0005500647,0.00008563096,0.00001304766,0.0001562449,0.0001179967,0.00001798253,0.0003358869],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05004679,"threshold_uncertainty_score":0.4357951,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03165917589675971,"score_gpt":0.3020189491864628,"score_spread":0.2703597732897031,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}